We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Register to vote Register by 18 June to vote in the General Election on 4 July.
Did you mean therapeutic
A research study of treatment integrity in prison addiction Therapeutic Communities.
Guidance on the organisation and use of democratic therapeutic communities in prisons.
A report identifying groups in the population at equivalent risk from severe COVID-19 outcomes to any condition in the highest-risk cohort.
The Department of Health and Social Care Therapeutics Clinical Review Panel determined which at-risk patient cohorts could be eligible for COVID-19 therapies.
For the treatment of severe acute malnutrition in children: a noninferiority individually randomized controlled efficacy clinical trial in Malawi
Guidance on Conditional Marketing Authorisations, exceptional circumstances Marketing Authorisations and national scientific advice
The authors eviewed publications comparing treatment outcomes of drug-susceptible TB patients diagnosed using Xpert vs. smear
This toolkit is for Innovation Passport holders following the Innovative Licensing and Access Pathway (ILAP) and provides activities to support the design and development of medicines.
There are changes to the legislation of Reference Medicinal Products (RMPs) used to support abridged marketing authorisation applications
A set of principles for understanding the impact of new variants on antiviral drugs and monoclonal antibodies
A qualitative process evaluation of the Enhancing Assessment of Common Therapeutic Factors (ENACT) scale
Apply for changes to your marketing authorisation, including minor variations type IA and IB, major variations type II and extensions.
This PAR covers the assessment of the application to increase the pack size of Neutrogena T/Gel Therapeutic Shampoo to a maximum of 500ml as a GSL medicine.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).